Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 501

1.

Metabolic syndrome and mental illness.

Newcomer JW.

Am J Manag Care. 2007 Nov;13(7 Suppl):S170-7. Review. Erratum in: Am J Manag Care. 2008 Feb;14(2):76.

2.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly..

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. French.

PMID:
19748369
3.

Antipsychotic medications: metabolic and cardiovascular risk.

Newcomer JW.

J Clin Psychiatry. 2007;68 Suppl 4:8-13. Review.

4.

Obesity among those with mental disorders: a National Institute of Mental Health meeting report.

Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL, Cope MB, Riley WT, Vreeland B, Hibbeln JR, Alpert JE.

Am J Prev Med. 2009 Apr;36(4):341-50. doi: 10.1016/j.amepre.2008.11.020.

PMID:
19285199
5.

Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses.

Newcomer JW.

J Clin Psychiatry. 2009;70 Suppl 3:30-6. doi: 10.4088/JCP.7075su1c.05. Review.

6.

Metabolic syndrome: epidemiology and consequences.

Sacks FM.

J Clin Psychiatry. 2004;65 Suppl 18:3-12. Review.

7.
8.

[Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].

Ruetsch O, Viala A, Bardou H, Martin P, Vacheron MN.

Encephale. 2005 Jul-Aug;31(4 Pt 1):507-16. Review. French.

PMID:
16389718
9.

Medical risk in patients with bipolar disorder and schizophrenia.

Newcomer JW.

J Clin Psychiatry. 2006;67 Suppl 9:25-30; discussion 36-42. Review.

10.

Metabolic issues and cardiovascular disease in patients with psychiatric disorders.

Casey DE.

Am J Med. 2005 Apr;118 Suppl 2:15S-22S. Review.

PMID:
15903291
12.

Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents.

Schneiderhan ME, Batscha CL, Rosen C.

Pharmacotherapy. 2009 Aug;29(8):975-87. doi: 10.1592/phco.29.8.975.

PMID:
19637951
13.

Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity.

Van Gaal LF.

Eur Neuropsychopharmacol. 2006 Sep;16 Suppl 3:S142-8. Review.

PMID:
16863690
14.

Metabolic risk during antipsychotic treatment.

Newcomer JW.

Clin Ther. 2004 Dec;26(12):1936-46. Review.

PMID:
15823759
15.

Prevalence of metabolic syndrome among Australians with severe mental illness.

John AP, Koloth R, Dragovic M, Lim SC.

Med J Aust. 2009 Feb 16;190(4):176-9.

PMID:
19220180
16.

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

Stahl SM, Mignon L, Meyer JM.

Acta Psychiatr Scand. 2009 Mar;119(3):171-9. doi: 10.1111/j.1600-0447.2008.01334.x. Review.

PMID:
19178394
17.

Medical risk in patients with bipolar disorder and schizophrenia.

Newcomer JW.

J Clin Psychiatry. 2006 Nov;67(11):e16.

18.

Schizophrenia and obesity: impact of antipsychotic medications.

Wirshing DA.

J Clin Psychiatry. 2004;65 Suppl 18:13-26. Review.

19.

[Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation].

Vanuzzo D, Pilotto L, Mirolo R, Pirelli S.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):6S-17S. Review. Italian.

PMID:
18773746
20.

Metabolism, lifestyle and bipolar affective disorder.

Morriss R, Mohammed FA.

J Psychopharmacol. 2005 Nov;19(6 Suppl):94-101. Review.

PMID:
16280342

Supplemental Content

Support Center